Anemia with elevation of growth differentiation factor-15 level in linezolid treated multidrug-resistant tuberculosis: Case series of three patients

Amaylia Oehadian; Prayudi Santoso; Dick Menzies; Rovina Ruslami

doi:10.1016/j.idcr.2022.e01591

Anemia with elevation of growth differentiation factor-15 level in linezolid treated multidrug-resistant tuberculosis: Case series of three patients

IDCases. 2022 Jul 29:29:e01591. doi: 10.1016/j.idcr.2022.e01591. eCollection 2022.

Authors

Amaylia Oehadian^{1

2}, Prayudi Santoso³, Dick Menzies⁴, Rovina Ruslami⁵

Affiliations

¹ Division of Hematology and Oncology Medic, Department of Internal Medicine Faculty of Medicine, Universitas Padjadjaran/ Dr. Hasan Sadikin General Hospital, Bandung, Indonesia.
² Doctoral Study Program, Faculty of Medicine, Universitas Padjadjaran, Bandung, West Java, Indonesia.
³ Division of Respirology and Critical Care, Department of Internal Medicine Faculty of Medicine, Universitas Padjadjaran/ Dr. Hasan Sadikin General Hospital, Bandung, Indonesia.
⁴ McGill International TB Centre Respiratory Epidemiology and Clinical Research Unit, Montreal, Canada.
⁵ Department of Biomedical Science, Division of Pharmacology, Universitas Padjadjaran/ Dr. Hasan Sadikin General Hospital, Bandung, Indonesia.

Abstract

Linezolid is now recommended as a first line drug for Multidrug Resistant Tuberculosis (MDR-TB). Previous studies reported hematologic toxicity as one of the main side effects. The mechanism of this toxicity is mitochondrial dysfunction, for which a biomarker is Growth differentiation factor-15 (GDF-15). There is no previous report about GDF-15 and its association with hematologic toxicity from Linezolid in the treatment of MDR-TB. We present three cases of MDR-TB involving severe anemia associated with linezolid who had GDF-15 elevation. These cases highlight the need for more research into the relationship between GDF-15 and hematologic toxicity in MDR-TB patients treated with linezolid.

Keywords: Anemia; Case Series; Growth Differentiation Factor-15; Linezolid; Multi-Drug Resistant Tuberculosis.

Publication types

Case Reports